News Releases

Activating the G protein-coupled estrogen receptor (GPER) – a receptor found on the surface of many normal and cancer tissues – has been shown to stop pancreatic cancer from growing, but may also make tumors more visible to the immune system and thus more susceptible to modern immunotherapy.

A blood test may be able to detect the most common form of pancreatic cancer while it is still in its early stages while also helping doctors accurately stage a patient’s disease and guide them to the appropriate treatment.

Chimeric antigen receptor (CAR) T cell therapy has been a game-changer for blood cancers but has faced challenges in targeting solid tumors. Now researchers from the Perelman School of Medicine at the University of Pennsylvania may have an alternative to T cell therapy that can overcome those challenges.

The deadly brain cancer glioblastoma (GBM) is often resistant to chemotherapy and radiation, but new research from the Perelman School of Medicine at the University of Pennsylvania and Penn’s Abramson Cancer Center shows targeting stromal cells – the cells that serve as the connective tissue of the organs – may be an effective way of overcoming that resistance.

Non-small cell lung cancer (NSCLC) patients with higher measures of tumor mutations that show up in a blood test generally have a better clinical response to PD-1-based immunotherapy treatments than patients with a lower measure of mutations.

Genetically-edited immune cells can persist, thrive, and function months after a cancer patient receives them, according to new data published by researchers from the Perelman School of Medicine at the University of Pennsylvania and Penn’s Abramson Cancer Center.

Some cancer cells refuse to die, even in the face of powerful cellular immunotherapies like CAR T cell therapy, and new research from the Abramson Cancer Center of the University of Pennsylvania is shedding light on why.

Proton therapy leads to significantly lower risk of side effects severe enough to lead to unplanned hospitalizations for cancer patients when compared with traditional radiation, while cure rates between the two groups are almost identical.